Results 51 to 60 of about 993 (163)

Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro. [PDF]

J Antimicrob Chemother
Abstract Objectives We sought to evaluate the comparative activity of rezafungin compared with caspofungin and other antifungal classes against biofilms from a large clinical panel of Candida strains (n = 167). Methods
Abduljalil H, Bartie K, Bal AM, Bal AM, Rautemaa-Richardson R, Williams C, Kean R, Ramage G.   +7 more
europepmc   +6 more sources

Antifungal resistance, combinations and pipeline: oh my!

Drugs in Context, 2023
Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover, Brandon K Hawkins, J Myles Keck, Katie E Barber, David A Cretella   +4 more
doaj   +1 more source

Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Infection: A Case Report [PDF]

, 2021
Rezafungin is a semisynthetic, long-acting echinocandin with broad-spectrum activity against many Candida species and Aspergillus species, including a subset of drug-resistant strains.
Ellison, Richard T, Siddiqui, Efaza, Adeel, Alina, Levitz, Stuart M, Qu, Ming D   +4 more
core   +1 more source

Echinocandins – structure, mechanism of action and use in antifungal therapy

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański, Sandra Chmielewska, Urszula Czyżewska, Marta Malinowska, Adam Tylicki   +4 more
doaj   +1 more source

Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects [PDF]

Clinical Pharmacology in Drug Development, 2019
AbstractRezafungin is a new echinocandin in development for treatment of candidemia and invasive candidiasis, and for prophylaxis of invasive fungal infections. Rezafungin is the first echinocandin to undergo definitive QT/QTc study. This phase 1, single‐center, randomized, double‐blind trial was conducted to assess effects of intravenous rezafungin vs
Shawn, Flanagan, Daniel B, Goodman, Alena, Jandourek, Terry, O'Reilly, Taylor, Sandison   +4 more
openaire   +2 more sources

Novel Antifungals and Aspergillus Section Terrei with Potpourri Susceptibility Profiles to Conventional Antifungals

Journal of Fungi, 2023
The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti, Jos Houbraken, Mike Birch, Cornelia Lass-Flörl   +3 more
doaj   +1 more source

2389. Effect of Rezafungin on QT Interval in Healthy Subjects [PDF]

Open Forum Infectious Diseases, 2018
BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation.
Flanagan, Shawn, Goodman, Daniel B, Rao, Pallavi, Jandourek, Alena, O’Reilly, Terry, Sandison, Taylor   +5 more
openaire   +1 more source

Metabolism, Excretion, and Mass Balance of [ ¹⁴ C]-Rezafungin in Animals and Humans

Antimicrobial Agents and Chemotherapy, 2022
Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus , and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [
Voon Ong, Sarah Wills, Deborah Watson, Taylor Sandison, Shawn Flanagan   +4 more
openaire   +2 more sources

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +1 more source

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial [PDF]

, 2023
Background: Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after ...
Ambasch G., Migliorino G. M., Young J. -A., Kollef M., Kern W. V., Zeng J., Feng S., Huang H., Maor Y., Xu J., Girardis M., Alexander B., Martinez A. R., Fortun-Abete J., Viale P., AlAgha R., Psichogiou M., Choi Y. H., Paterson D., Albrecht S. J., Wang F. -D., Garcia-Diaz J., Papastamopoulos V., Patterson T. F., Midturi J., Vazquez J., Cascio A., Ferrer R., Nseir S., Horcajada Gallego J. P., Permpalung N., Chotiprasitsakul D., Luo H., Chen Y. -H., Baffoe-Bonnie A., Hussein O., Forel J. -M. F. R., Jauregui-Peredo L., Huang Y., Raz-Pasteur A., Armestar Rodriguez F., Ho M. -W., Weber G., Chaiwarith R., Das A. F., Denis B., Ferre Colomer M. A., Lopez Cortes L. E., Chen Y. -C., Riera F., Poromanski I. G., Rogers B., Odabasi Z., Rahav G., Wang S., Merelli M., Sganga G., Johnson M., Teschner D., Yilmaz M., Ben-Ami R., Peck K. R., Weng J., Poromanski I., Dupont H., Honore P., Belkhir L., Peng Z., Slavin M., Honore P. M., Mussini C., Powell D., Vergidis P., Kett D. H., Sandison T., Munoz Garcia de Paredes P., Chung J. W., Puah S. H., Yavuz S., Dignani C., Soriano A., McCarty T., Khawcharoenporn T., Tao Z., Al-Obaidi M., Plantefeve G. J., Kim Y. K., Danion F., Sanchez Vallejo G., Kullberg B. J., Van Wijngaerden E., Kotanidou A., Huang P. -Y., Chai L. Y., Jung D. S., Lin Q., Ramos Ramos J. C., Pullman J., Akova M., Boutoille D., He F., Strahilevitz J., Intalapaporn P., Mootsikapun P., Koehler P., Yao L., Nseir W., Rodriguez Alvarez R. J., Tancheva D. M., Zhang Y., Pappas P. G., Jutivorakool K., Roilides E., Zarate A. H., Alangaden G., Dictar M. O., Mylonakis E., Cornely O. A., Azap A., Chen S., Morrissey O., Bassetti M., Hites M., Diaz Santos E., Diltoer M., Restrepo Castro C. A., Thompson G. R., Choi J. Y., Jaruratanasirikul S., Lachiewicz A., Merino Amador P., Roblot F., Spec A., Luzzati R., Sipsas N., Chayakulkeeree M., Mira J. -P.   +136 more
core   +3 more sources